4.7 Article

3,5-Diphenylpent-2-enoic Acids as Allosteric Activators of the Protein Kinase PDK1: Structure-Activity Relationships and Thermodynamic Characterization of Binding as Paradigms for PIF-Binding Pocket-Targeting Compounds

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 52, 期 15, 页码 4683-4693

出版社

AMER CHEMICAL SOC
DOI: 10.1021/jm9001499

关键词

-

资金

  1. Deutsche Forschungsgerneinschaft [BI 1044/2-2]
  2. Europrofession Foundation (Saarbrucken, Germany)
  3. Deutsche Jose Carreras Leukamie-Stiftung [DJCLS R 06/07]
  4. German Federal Ministry or Education and Science

向作者/读者索取更多资源

The modulation of protein kinase activities by low molecular weight compounds is a major goal of current pharmaceutical developments. In this line, important efforts are directed to the development of drugs targeting the conserved ATP binding site. However, there is very little experience on targeting allosteric, regulatory sites, different from the ATP binding site, in protein kinases. Here we describe the synthesis, cell-free activation potency, and calorimetric binding analysis of 3,5-diphenylpent-2-enoic acids and derivatives as allosteric modulators of the phosphoinositide-dependent kinase-1 (PDK 1) catalytic activity. Our SAR results combined with thermodynamic binding analyses revealed both favorable binding enthalpy and entropy and confirmed the PIF-binding pocket of PDK I as a druggable site. In conclusion, we defined the minimal structural requirements for compounds to bind to the PIF-binding pocket and to act as allosteric modulators and identified two new lead structures (12Z and 13Z) with predominating binding enthalpy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Identification of Key Phospholipids That Bind and Activate Atypical PKCs

Suresh Velnati, Sara Centonze, Federico Girivetto, Daniela Capello, Ricardo M. Biondi, Alessandra Bertoni, Roberto Cantello, Beatrice Ragnoli, Mario Malerba, Andrea Graziani, Gianluca Baldanzi

Summary: PKC zeta and PKC iota/lambda form the atypical protein kinase C subgroup, characterized by their regulation distinct from conventional PKCs. Both PKC zeta and PKC iota interact with phosphatidic acid and phosphatidylserine, while PKC iota uniquely binds to phosphatidylinositol-monophosphates. Additionally, phosphatidylinositol 4-phosphate specifically activates PKC iota, indicating a specific regulation of PKC iota by certain membrane lipids.

BIOMEDICINES (2021)

Article Chemistry, Medicinal

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface

Markus Hartmann, Jessica Huber, Jan S. Kramer, Jan Heering, Larissa Pietsch, Holger Stark, Dalibor Odadzic, Iris Bischoff, Robert Fuerst, Martin Schroeder, Masato Akutsu, Apirat Chaikuad, Volker Doetsch, Stefan Knapp, Ricardo M. Biondi, Vladimir V. Rogov, Ewgenij Proschak

Summary: The study revealed that the human Atg8 family proteins LC3A and LC3B can be inhibited by the small molecule novobiocin, laying the foundation for the development of more potent chemical probes and potential applications in autophagy-mediated degraders. This study also reports the first nonpeptide inhibitors for these protein interaction targets.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Hematology

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K

Afsar Ali Mian, Isabella Haberbosch, Hazem Khamaisie, Abed Agbarya, Larissa Pietsch, Elizabeh Eshel, Dally Najib, Claudia Chiriches, Oliver Gerhard Ottmann, Oliver Hantschel, Ricardo M. Biondi, Martin Ruthardt, Jamal Mahajna

Summary: The study found that crizotinib can effectively inhibit the growth of Ph+ leukemia cells without affecting Ph- cells. Its efficacy has been validated in different models, demonstrating a unique dual mechanism of action.

ANNALS OF HEMATOLOGY (2021)

Article Biochemistry & Molecular Biology

Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability

Georg Dultz, Sanjay K. Srikakulam, Michael Konetschnik, Tetsuro Shimakami, Nadezhda T. Doncheva, Julia Dietz, Christoph Sarrazin, Ricardo M. Biondi, Stefan Zeuzem, Robert Tampe, Olga Kalinina, Christoph Welsch

Summary: The Q80K polymorphism in the NS3-4A protease of hepatitis C virus is associated with treatment failure of direct acting antiviral agents and is highly prevalent in genotype 1a infections. This polymorphism destabilizes protease protein fold and reduces peptide substrate turnover. Epistatic substitutions at residues 91 and 174 stabilize the protein fold but inversely correlate with enzymatic activity, contributing to viral fitness through mechanisms not directly related to RNA replication.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Article Biochemistry & Molecular Biology

Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile: Optimization of the 2,4-substituents

Dina Aboushady, Sari S. Rasheed, Jennifer Herrmann, Ahmed Maher, Ebaa M. El-Hossary, Eslam S. Ibrahim, Ashraf H. Abadi, Matthias Engel, Rolf Mueller, Mohammad Abdel-Halim, Mostafa M. Hamed

Summary: Novel compounds with potent antibacterial activity have been designed and synthesized, showing the ability to inhibit a range of bacteria, including resistant strains, while maintaining a good safety profile.

BIOORGANIC CHEMISTRY (2021)

Article Chemistry, Medicinal

Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects

Yasmeen T. AlNajjar, Moustafa Gabr, Ahmed K. ElHady, Mohamed Salah, Gerrit Wilms, Ashraf H. Abadi, Walter Becker, Mohammad Abdel-Halim, Matthias Engel

Summary: The study found that dual inhibitors with higher selectivity for Dyrk1A and inhibition of alpha-synuclein aggregation present a potential novel therapeutic strategy for Parkinson's disease. Compound b27, displaying the highest inhibitory potency and selectivity, could be a promising drug candidate for PD treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Chemistry, Medicinal

Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile: Modification of the benzenoid part

Sarah H. Megahed, Sari Rasheed, Jennifer Herrmann, Ebaa M. El-Hossary, Yahia I. El-Shabrawy, Ashraf H. Abadi, Matthias Engel, Rolf Mueller, Mohammad Abdel-Halim, Mostafa M. Hamed

Summary: The resistance of bacteria to current antibiotics necessitates the development of new antibacterial agents that are safe and effective against multi-drug resistant strains. Compound I has been identified as a promising candidate with broad-spectrum antibacterial activity and low cytotoxicity. In this study, we further optimized Compound I by modifying the benzenoid part and substituents at positions 6 and 7. The resulting compounds showed significant antibacterial activity against pathogenic bacteria, including drug-resistant strains. Compound 12 exhibited 2-4 times improvement in activity compared to Compound I against specific bacteria, and these compounds were also found to be safe for human cells.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)

Article Chemistry, Medicinal

Development of novel conformationally restricted selective Clk1/4 inhibitors through creating an intramolecular hydrogen bond involving an imide linker

Dalia S. El-Gamil, Ahmed K. ElHady, Po-Jen Chen, Tsong-Long Hwang, Ashraf H. Abadi, Mohammad Abdel-Halim, Matthias Engel

Summary: In this study, a novel series of potent and selective Clk1/4 inhibitors were discovered and characterized. These inhibitors show promising anti-cancer activities and have the potential to be used in clinical settings.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Medicine, Research & Experimental

Nanoparticle Fraught Liposomes: A Platform for Increased Antibiotic Selectivity in Multidrug Resistant Bacteria

Suzan Fangary, Mohammad Abdel-Halim, Reem K. Fathalla, Raghda Hassan, Noha Farag, Matthias Engel, Samar Mansour, Salma N. Tammam

Summary: This article presents a method for achieving selective drug delivery and reducing toxicity through nanoparticle-loaded liposomes. By adjusting the uptake of nanoparticles in bacterial cells and mammalian cells, the antibacterial actions can be enhanced while minimizing toxicity to mammalian cells.

MOLECULAR PHARMACEUTICS (2022)

Article Chemistry, Medicinal

Development of (4-Phenylamino)quinazoline Alkylthiourea Derivatives as Novel NF-κB Inhibitors

Sarah S. Darwish, Po-Jen Chen, Mostafa M. Hamed, Reem A. Wagdy, Shun-Hua Chen, Ashraf H. Abadi, Mohammad Abdel-Halim, Tsong-Long Hwang, Matthias Engel

Summary: This study developed new drugs that selectively inhibit the activation of NF-kappa B in macrophages, which may help treat inflammatory diseases with fewer side effects.

PHARMACEUTICALS (2022)

Article Biochemistry & Molecular Biology

From EGFR kinase inhibitors to anti-inflammatory drugs: Optimization and biological evaluation of (4-(phenylamino)quinazolinyl)-phenylthiourea derivatives as novel NF-?B inhibitors

Reem A. Wagdy, Po-Jen Chen, Mostafa M. Hamed, Sarah S. Darwish, Shun-Hua Chen, Ashraf H. Abadi, Mohammad Abdel-Halim, Tsong-Long Hwang, Matthias Engel

Summary: We designed and synthesized novel NF-kappa B inhibitors, which showed potential applications in suppressing cytokine release and selectively depleting macrophages.

BIOORGANIC CHEMISTRY (2022)

Review Chemistry, Medicinal

An overview of cdc2-like kinase 1 (Clk1) inhibitors and their therapeutic indications

Ahmed K. ElHady, Dalia S. El-Gamil, Ashraf H. Abadi, Mohammad Abdel-Halim, Matthias Engel

Summary: Clk1 has been identified as a promising target for the treatment of various diseases, especially those related to deregulated alternative splicing. Clinical trials of small molecule inhibitors targeting Clk1 are underway for the treatment of solid cancer, which is promoted by oncogenic protein variants derived from alternative splicing. In addition, Clk1 has been implicated in the progression of Alzheimer's disease. However, most Clk1 inhibitors lack sufficient selectivity, affecting other Clk isoforms and Dyrk kinases.

MEDICINAL RESEARCH REVIEWS (2023)

Article Chemistry, Medicinal

Discovery of novel 5-methoxybenzothiophene hydrazides as metabolically stable Clk1 inhibitors with high potency and unprecedented Clk1 isoenzyme selectivity

Dalia S. El-Gamil, Ahmed K. ElHady, Po-Jen Chen, Tsong-Long Hwang, Ashraf H. Abadi, Mohammad Abdel-Halim, Matthias Engel

Summary: Clk1 kinase is a key modulator of pre-mRNA alternative splicing and could be a potential target for treating various tumors, Duchenne's muscular dystrophy, and viral infections. A new 5-methoxybenzothiophene scaffold was developed, enabling selective inhibition of Clk1 among isoenzymes. The derivatives 26a and 27a showed unprecedented selectivity and good growth inhibitory activity in cancer cells.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Identification and Biochemical Characterization of Pyrrolidinediones as Novel Inhibitors of the Bacterial Enzyme MurA

Reem K. Fathalla, Wolfgang Froehner, Chantal D. Bader, Patrick D. Fischer, Charlotte Dahlem, Deep Chatterjee, Sebastian Mathea, Alexandra K. Kiemer, Haribabu Arthanari, Rolf Muller, Mohammad Abdel-Halim, Christian Ducho, Matthias Engel

Summary: This study reports a novel class of reversible MurA inhibitors that can inhibit both wild type MurA and fosfomycin-resistant MurA C115D mutant, showing potential for inhibiting cell wall synthesis. The most potent inhibitor 46 exhibits good stability and non-toxicity.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Chemistry, Medicinal

Targeting the binding pocket of the fluorophore 8-anilinonaphthalene-1-sulfonic acid in the bacterial enzyme MurA

Reem K. Fathalla, Matthias Engel, Christian Ducho

Summary: 8-Anilinonaphthalene-1-sulfonic acid (ANS) is a fluorescent probe commonly used to detect conformational changes in proteins. This study discovered that ANS can inhibit the activity of various isoforms of MurA and identified a more potent ANS analog. These findings highlight the potential of targeting the ANS binding pocket for the development of antibiotics.

ARCHIV DER PHARMAZIE (2023)

暂无数据